Literature DB >> 3924607

Evaluation of three serological tests for detection of antibody to Pseudomonas aeruginosa in human sera.

T L Pitt, H C Todd, C A Mackintosh, S W Im.   

Abstract

Four hundred and ninety-five sera from 325 patients from whom Pseudomonas aeruginosa had been isolated and 86 control sera were tested for antibody by indirect haemagglutination tests (HAT) and complement fixation tests (CFT) using a polyvalent pseudomonas serotype-specific vaccine antigen, PEV-02. Sera were also tested by countercurrent immunoelectrophoresis (CIE) for precipitins to a species-specific protein antigen. Control sera gave titres of 160 or less by HAT and 20 or less by CFT. 2-Mercaptoethanol resistant antibody titres (immunoglobulin G) were below 40 for all control sera and none of the latter contained precipitins to common antigen. Of 325 patients, 156 (48%) gave titres of 320 or greater by HAT and of these, 114 (73%) showed elevated immunoglobulin G titres. Less patients with positive blood cultures than expected were positive by HAT and more patients with bone infections gave raised immunoglobulin G titres than expected. Cystic fibrosis patients were invariably seropositive by all tests. There was a correlation between positive CIE and CFT tests, especially in patients who were positive by HAT. Approximately half of 83 patients tested gave a serotype-specific antibody response. The tests were of little value in confirming clinically evident acute infections, but in cases of doubtful infection they did provide confirmatory evidence of an antibody response in approximately one-third of patients culture-positive for Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924607     DOI: 10.1007/bf02013596

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  20 in total

1.  Technique of complementfixation test applicable to the diagnosis of virus diseases.

Authors:  C M BRADSTREET; C E TAYLOR
Journal:  Mon Bull Minist Health Public Health Lab Serv       Date:  1962-05

2.  Pseudomonas endocarditis: hemagglutinating antibodies to Fisher-Devlin-Gnabasik immunotypes in sera.

Authors:  M P Reyes; M W Fisher; A M Lerner
Journal:  J Lab Clin Med       Date:  1974-06

3.  Type-specific immunity in pseudomonas diseases.

Authors:  J G Crowder; M W Fisher; A White
Journal:  J Lab Clin Med       Date:  1972-01

4.  Pseudomonas aeruginosa: serogroups and antibody response in patients with neoplastic diseases.

Authors:  F Diaz; E Neter
Journal:  Am J Med Sci       Date:  1970-05       Impact factor: 2.378

5.  Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.

Authors:  J D Klinger; D C Straus; C B Hilton; J A Bass
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

6.  An antigen common to a wide range of bacteria. I. The isolation of a 'common antigen' from Pseudomonas aeruginosa.

Authors:  D Sompolinsky; J B Hertz; N Høiby; K Jensen; B Mansa; Z Samra
Journal:  Acta Pathol Microbiol Scand B       Date:  1980-06

7.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

8.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

9.  Enzyme-linked immunosorbent assay for detection of Pseudomonas aeruginosa Lipopolysaccharides.

Authors:  H Kusama
Journal:  J Clin Microbiol       Date:  1983-02       Impact factor: 5.948

10.  Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients.

Authors:  K E Crowe; J A Bass; V M Young; D C Straus
Journal:  J Clin Microbiol       Date:  1982-01       Impact factor: 11.677

View more
  6 in total

1.  Enzyme-linked immunosorbent assay for detection of Pseudomonas aeruginosa H (flagellar) antigen.

Authors:  T C Montie; T R Anderson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

2.  Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay.

Authors:  S S Pedersen; F Espersen; N Høiby
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

3.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

4.  Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia.

Authors:  A Brauner; S J Cryz; M Granström; H S Hanson; L Löfstrand; B Strandvik; B Wretlind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

5.  Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; N Høiby; G H Shand; R S Conrad; C Galanos
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

Review 6.  Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.

Authors:  T L Pitt
Journal:  J R Soc Med       Date:  1986       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.